focus -WSS

focus

author：focus 2025-09-03 14:42:08 - browse：75

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Venture capital firm's plans to take over Akron hospital face hurdles

Wikipedia

hotspot

WSS

White House pharmacy plagued with problems, investigation finds

Addiction doctors spar with methadone clinics over legislation

First Opinion Podcast: What happens when kids become caregivers?

Addiction doctors spar with methadone clinics over legislation

Philips to halt sales of sleep apnea machines in U.S.

Wegovy leads to weight loss. Can it treat depression, too?

hotspot

focus

focus

New air purifier tech could be key to improving indoor air quality

Dark money group runs ads on China biotech bill

Sports medicine is finally prioritizing gender equality

Investment in vaccine development is lagging, report finds

Activists slam private health insurers over coverage restrictions

Vertex non

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

What does generative AI mean for health care? We asked experts

Why you shouldn’t ask, “What country has the best health care?”

focus

First Opinion Podcast: What happens when kids become caregivers?

Biohaven protein

Report: NIH

Medicare Advantage insurers face 0.2% cut to 2025 payments

Akili, maker of video game for ADHD, to be acquired for 34 million

Latest bird flu infection made farmworker sicker than earlier cases

explore

Wikipedia

hotspot

Wikipedia